胃癌治疗现状及2008ASCO进展PPT.ppt

胃癌治疗现状及2008ASCO进展;胃癌治疗有效的化疗药物;;FP vs FAM vs UFTM: JCOG 9912 trial;;E Epirubicin 50 mg/m2 iv C Cisplatin 60 mg/m2 iv F PVI 5-FU 200 mg/m2/dayq3w;Regimen;REAL-2: overall survival for platinum comparison (per protocol);Arm;Toxicity (% of patients);;Best Overall Response (ITT);Time to Treatment Failure (ITT);FLO vs FLP: subgroup of patients over 65 years;Grade ? Hematological and Neurosensory toxicities;RANDO MIS ATION;XP vs FP: non-inferior PFS;XP vs FP: trend to superior PFS;Superior response rate with XP vs FP;DCF Docetaxel 75 mg/m2 over 1 h, Day 1 Cisplatin 75 mg/m2 over 1–3 h, Day 1 5-FU 750 mg/m2/day over 5 days, q3w (n=227);Log-rank p=0.0004 Hazard ratio: 1.47 (95% CI: 1.19?1.83) Risk reduction: 32.1%;OS;DCF;TAX 325 Clinical Benefit: time to definitive worsening of KPSa;Patients (%); % of evaluable patients;TAX325: Conclusions andinterpretations;V306: FUFIRI vs FP as 1st Line Chemotherapy for AGC;V306: FUFIRI vs FP as 1st Line Chemotherapy for AGC;- Center - PS - Unresectable vs recurent, adj Crx vs recurrent, no adj Crx;JCOG 9912 Trial; Results;R A N D O M I S A T I O N;Results of SPRITS Trial;;R A N D O M I S A T I O N;;Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. ;;;Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study ;;;Meta-analysis of chemotherapy inadvanced gastric cancer;Meta-analysis of chemotherapy inadvanced gastric cancer;GATE phase II trial of first-line docetaxel –oxaliplatin in advanced gastric cancer;;Median TTP: 5.4 months; Ruihua Xu1, Bing Han1, Feng Wang1, Huiyan Luo1,Yanxia Shi1, Yuhong Li1, Miaozhen Qiu1, Wenqi Jiang1, Youjian He1, Zhong-zhen Guang1 1. Department of Medical Oncology, Sun Yat-sen University Cancer Center,Guangzhou GD, CHINA